topiramato

AIM: The aim of this study was to evaluate the efficacy and safety of tiapride compared to topiramate as a prophylactic in chronic migraine. PATIENTS AND METHODS: The study was conducted under randomised and double blind conditions. A total of 56 patients aged 18-65 years with chronic migraine were assigned to two treatment arms: tiapride, 100 mg twice daily, or topiramate, 25 mg twice daily, for 12 weeks. The primary endpoint was the change in the monthly average number of migraine days...

OBJECTIVE: To identify current evidence on the use of topiramate for refractory status epilepticus. METHODS: We reviewed the literature to investigate the efficacy of topiramate in the treatment of refractory status epilepticus. The search terms used were "status epilepticus", "refractory", "treatment" and "topiramate". No restrictions were used. RESULTS: The search yielded 487 articles that reported using topiramate as a treatment for refractory status epilepticus and its outcomes...

A 36 year-old woman with idiopathic intracranial hypertension was treated with topiramate and acetazolamide. The patient was followed-up for 2 years, with a relationship between neurosensory detachments and topiramate being established, with recurrences after the introduction of topiramato and improvement after its withdrawal. These findings point topiramate as a possible cause of the clinical picture. Topiramate may cause retinal and macular neurosensory detachments. Although the ciliochoroidal effusion cases caused by this drug are well-known, its retinal side effects are less common...

PURPOSE: To review the world literature about drug induced uveitis. METHODS: We used the OMS and Naranjo criteria of causality of adverse drug reactions to classify the causes of drug induced uveitis. These have been classified into certain, probable and possible causes. We described the clinical features associated with each drug. RESULTS: Certain causes of uveitis are byphosphonates, topiramato and metipranolol eyedrops. Probable causes are rifabutin, sulfonamides, cidofovir, immunorecovery in patients following HAART therapy, topical corticosteroids, latanoprost, and intravitreous triamcinolone acetate...

OBJECTIVE: The characteristics of the new anti-epileptic drug topiramato (TPM) are described: multiple mechanism of action, favourable pharmaco-kinetics, wide therapeutic range and is relatively well tolerated, Development. Its initial usefulness in patients with partial crises resistant to other anti-epileptic drugs has been shown. TPM is equally effective in primary generalized crises, and in patients with the Lennox-Gastaut syndrome, in whom no problem of tolerance has been seen. CONCLUSION: TPM is a valuable drug for the treatment of epilepsy...